Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: structure-activity relationships.

c-myb is a proto-oncogene encoding a transcription factor which is highly expressed in hematopoietic progenitor cells. It regulates the expression of genes important for lineage determination, cell proliferation, and differentiation. Deregulation of c-myb expression is known to be involved in the development of human tumors, especially certain types of leukemia and breast and colon cancer. The c-Myb protein has thus been identified as an interesting therapeutic target. We recently discovered that some sesquiterpene lactones suppress Myb-dependent gene expression which is a new mechanism for these natural products' potential anti-cancer activity. We developed a test system to screen compounds for inhibitory activity on Myb-inducible reporter gene activation. Using this system we have now investigated 60 sesquiterpene lactones for their capacity to inhibit c-Myb-dependent gene activation. The IC50 values were in a range between 0.7 and >30 μM. The furanoheliangolide goyazensolide and the pseudoguaianolide helenalin acetate (IC50 = 0.6 and 0.7 μM, respectively) represent the most active inhibitors of c-Myb dependent gene expression found up to present. Control measurements for cell viability (MTS assay) proved that the observed activity on c-Myb dependent gene expression is not a function of cytotoxicity/unspecific cell damage. Structure-activity relationships were investigated by a QSAR approach based on flexible alignment of the most active compounds and a common pharmacophore model. These investigations resulted in a QSAR model which indicates that the potency of inhibitory activity on c-Myb-dependent transcription does not only depend on the presence of reactive Michael-acceptor features but also on their optimal spatial arrangement in the molecule.

[1]  J. Heilmann,et al.  Quantitative Structure-Cytotoxicity Relationships of Sesquiterpene Lactones derived from partial charge (Q)-based fractional Accessible Surface Area Descriptors (Q_frASAs) , 2002 .

[2]  K. Klempnauer,et al.  Expression of mouse c-myb during embryonic development. , 1995, Oncogene.

[3]  Atta-ur- Rahman,et al.  Studies in natural products chemistry , 1988 .

[4]  E. Reddy,et al.  The myb gene family in cell growth, differentiation and apoptosis , 1999, Oncogene.

[5]  K. Rajewsky,et al.  Critical functions for c-Myb at three checkpoints during thymocyte development , 2004, Nature Immunology.

[6]  K. Klempnauer,et al.  Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I , 2012, Leukemia.

[7]  J. Lipsick,et al.  Transformation by v-Myb , 1999, Oncogene.

[8]  W. Alexander,et al.  Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Rushton,et al.  Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins , 2003, Oncogene.

[10]  K. Weston,et al.  Myb proteins regulate the expression of diverse target genes , 2005, Oncogene.

[11]  G. Anderson,et al.  Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c‐Myb , 2003, The EMBO journal.

[12]  S. Swerdlow,et al.  A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis , 1991, Cell.

[13]  I. Merfort.  Perspectives on sesquiterpene lactones in inflammation and cancer. , 2011, Current drug targets.

[14]  K. Weston.  Myb proteins in life, death and differentiation. , 1998, Current opinion in genetics & development.

[15]  L. Tarantino,et al.  c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. , 2005, Developmental cell.

[16]  T. Schmidt,et al.  Structure-Activity Relationships of Sesquiterpene Lactones , 2006 .

[17]  A. Plachetka,et al.  Myb-induced Chromatin Remodeling at a Dual Enhancer/Promoter Element Involves Non-coding RNA Transcription and Is Disrupted by Oncogenic Mutations of v-myb* , 2009, The Journal of Biological Chemistry.

[18]  R. Brun,et al.  Quantitative Structure − Antiprotozoal Activity Relationships of Sesquiterpene Lactones † , 2009, Molecules.

[19]  S. Ness,et al.  Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb , 2006, Oncogene.

[20]  Robert G. Ramsay,et al.  MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.

[21]  P. Vandenabeele,et al.  Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide , 2012, Anti-cancer drugs.

[22]  B. Lüscher,et al.  Revisiting a selection of target genes for the hematopoietic transcription factor c-Myb using chromatin immunoprecipitation and c-Myb knockdown. , 2007, Blood cells, molecules & diseases.

[23]  H. Clevers,et al.  c-Myb is required for progenitor cell homeostasis in colonic crypts , 2007, Proceedings of the National Academy of Sciences.

[24]  K. Rajewsky,et al.  c-Myb is critical for B cell development and maintenance of follicular B cells. , 2005, Immunity.

[25]  K. Klempnauer,et al.  v-Myb Mediates Cooperation of a Cell-Specific Enhancer with the mim-1 Promoter , 2005, Molecular and Cellular Biology.